Glossary of Pharmaceutical Terms and Acronyms

This glossary provides brief descriptions of selected terms and concepts related to the pharmaceutical industry. It is not intended to be a comprehensive list of relevant terms or to provide a complete explanation of the included terms and concepts.

**AAC**: Actual Acquisition Cost. Usually a surveyed pharmacy drug acquisition cost. It is used by some state Medicaid agencies as a basis for reimbursement.

**aBLA**: Abbreviated Biologics License Application. The pathway for FDA approval of biosimilar products.

**ADR**: Adverse Drug Reaction.

**AMP**: Average Manufacturer Price. A statutorily defined average price measure for drug products distributed to the retail class of trade that is used to determine Medicaid rebates and WAMP for generic drugs. It measures prices charged by manufacturers, net of discounts and rebates (excluding certain federal programs). Although it is reported by manufacturers to CMS, it is not publicly available.

**ANDA**: Abbreviated New Drug Application. The pathway for FDA approval that is generally used for generic drugs. See also NDA.

**API**: Active Pharmaceutical Ingredient. Also referred to as “Active Ingredient.”

**ASP**: Average Sales Price. A statutorily defined price measure used to determine reimbursement for Medicare Part B covered drugs (i.e., physician-administered drugs). It measures average prices charged by manufacturers to all purchasers, net of discounts and rebates (excluding certain federal programs) and is reported by manufacturers to CMS. The payment limits derived from the ASPs are publicly available.
At-Risk Launch: Typically refers to a situation where a manufacturer that is a defendant in a patent infringement lawsuit launches its product prior to full resolution of pending litigation.

Authorized Generic (AG): A brand name drug with an approved NDA that is marketed as a generic.

AWP: Average Wholesale Price. A reference benchmark that may be used in determining the reimbursement amount for a drug.

Batch: A specific quantity of material produced in a process such that it is expected to be homogenous within specified limits.

Best Price: A statutorily defined measure of a minimum price for drug products distributed to the retail class of trade that is used to determine Medicaid rebates. It measures the lowest prices charged by manufacturers, net of discounts and rebates (excluding certain nominal transactions and federal programs). Although it is reported by manufacturers to CMS, it is not publicly available.

Biologic: A drug product produced from or by biological (living) organisms. These products are often referred to as large molecule drugs because of the complexity of their chemical makeup.

Biosimilar: A biologic that is demonstrated to be similar to a reference biologic product. There is an abbreviated approval pathway for these products. See aBLA. These products may not be considered interchangeable with the reference biologic.

BLA: Biologic License Application. The pathway for FDA approval of biologic drugs. See also aBLA.

BPCIA: Biologics Price Competition and Innovation Act (2009). Created the abbreviated pathway for FDA approval of biosimilar products. See aBLA.

Branded Product: A drug marketed under a brand name. Typically refers to products approved under an NDA or BLA/aBLA, though products approved under an ANDA may also be marketed with a brand name.

CBER: Center for Biologics Evaluation and Research.

CDER: Center for Drug Evaluation and Research.

CGMP: Current Good Manufacturing Practices. FDA regulations that govern drug manufacturing processes.

Chargeback: Typically a payment made by a manufacturer to a wholesaler to reimburse the wholesaler for a discount that a manufacturer is contractually obligated to provide to the wholesaler’s customer.

Clinical Trial: Testing of an IND in human subjects.
**CMS**: Centers for Medicare and Medicaid Services.

**Compounding**: Practice in which a pharmacist combines, mixes, or alters ingredients of a drug to create a medication.

**Contract Price**: A negotiated price for a drug product.

**Coinsurance**: A fixed percentage of the cost of a prescription drug at the point of sale that a pharmacy benefit plan requires the patient to pay.

**Copay Coupon**: A voucher distributed to patients by the manufacturer of a drug that can be redeemed to cover at least some of the patients’ out-of-pocket costs for the drug.

**Copayment**: A flat payment amount required by a pharmacy benefit plan that the patient is responsible for paying at the pharmacy point of sale when obtaining a prescription. These generally vary by formulary tier.

**CRO**: Contract Research Organization.

**DAW**: Dispense as Written. A notation by a prescriber that can dictate whether generic substitution will occur when a prescription is filled.

**Detailing**: Efforts by sales representatives for drug manufacturers to educate prescribers about their products.

**Direct Contract**: Contract between a drug manufacturer and a customer (such as a retail pharmacy) where the product does not pass through an intermediary wholesaler.

**Dispensing Fee**: A contracted fee paid to a pharmacy for the service of dispensing/filling a prescription and advising patients. It does not include the drug cost, which is often referred to as the ingredient cost.

**Distributor**: Similar to a wholesaler, but generally does not manage indirect contracts and chargebacks, or run source programs.

**DTC**: Direct to Consumer Advertising (also called DTCA).

**EAC**: Estimated Acquisition Cost. Used in Medicaid statutes to refer to prices to be used in pharmacy reimbursement (e.g., the AAC or NADAC can be used by a state as its EAC).

**FDA**: US Food and Drug Administration.

**Fill/Finish**: Manufacturing step involving putting a drug into a container/delivery system under aseptic conditions.

**Formulary**: A list of covered drugs provided by a pharmacy benefit plan describing the level of coverage for each product, and any limits, restrictions, or exclusions to that coverage.
**FUL**: Federal Upper Limit. A statutorily defined upper limit for Medicaid reimbursement of generic drugs.

**GDUFA**: Generic Drug User Fee Amendments (2012/2017 updated GDUFA II).

**Generic Product**: A drug marketed under its chemical name; generally refers to small molecule products approved by the FDA under an ANDA.

**GLP**: Good Laboratory Practices.

**GPO**: Group Purchasing Organization. An entity that aggregates the purchases of healthcare providers (e.g., hospitals) and contracts with suppliers on their behalf to enable price discounts and efficiencies.

**Hatch-Waxman Act**: Also known as the Drug Price Competition and Patent Term Restoration Act (1984). Among other provisions, created an abbreviated pathway for FDA approval of generic drug products, statutory exclusivity provisions for new and patented drug products, and a 180-day exclusivity period for ANDA filers that challenge patents listed in the Orange Book.

**HCPCS**: Healthcare Common Procedure Coding System. A coding system used by CMS for Medicare to identify drugs and procedures for reimbursement. In this system, drugs are typically listed with a “J” or “Q” followed by a four-digit number.

**IND**: Investigational New Drug.

**Indirect Contract**: Contract between a manufacturer and a customer (such as a retail pharmacy) where product passes through intermediary wholesaler.

**J-Code**: Common term for Medicare HCPCS billing codes for Medicare Part B drugs.

**IRB**: Institutional Review Board.

**Label**: FDA-required labeling provided with medicines. Provides prescribing information such as approved indications, contra-indications, common side effects, and recommended dosing.

**Labeler**: The entity that manufacturers, repacks, or distributes a drug product. See NDC.

**MAC**: Maximum Allowable Cost. Upper limit set by an insurer (Medicaid or private plans) for the reimbursement of multiple-source generic drugs.

**MCO**: Managed Care Organization.

**Medicaid**: A state/federal system of health insurance for those requiring financial assistance. Each state is responsible for its Medicaid program design, operation, and partial funding within federal guidelines managed by the CMS.

**Medicare Part A**: Federal hospital insurance program for the elderly (qualifying age is generally 65).
Medicare Part B: A federal health insurance program for the elderly (qualifying age is generally 65). Covers non-hospital medical services and supplies, including injectable drugs delivered in an office setting.

Medicare Part D: Optional additional Medicare coverage for prescription drugs. Covers the costs of medications not covered by Medicare Part B (e.g., oral medications obtained through a pharmacy).

NADAC: National Average Drug Acquisition Cost. A surveyed pharmacy drug invoice cost provided by CMS for use in drug reimbursement by state Medicaid programs.

NDA: New Drug Application. The pathway for FDA approval generally used for small molecule drugs.

NDC: National Drug Code. A numeric code that uniquely identifies drug products. The code includes three segments that identify the labeler, the product, and the packaging.

NRx: New Prescriptions.

Orange Book: The FDA’s list of Approved Drug Products with Therapeutic Equivalence Evaluations.

OTC: Over-the-counter. Typically refers to a drug product that can be purchased without a prescription.

OOP Cost: Out-of-pocket cost. The cost that the patient pays at the pharmacy point of sale. For an insured patient being dispensed a covered drug, this cost will include any coinsurance amount or copayment.

P&T Committee: Pharmacy and Therapeutics Committee. A group of health care providers and other professionals working on behalf of a managed care plan, hospital, or pharmacy benefit manager to evaluate and manage a drug formulary.

Paragraph IV Certification: A certification from an ANDA applicant that a patent (or patents) listed in the Orange Book for the brand-name reference product is invalid, unenforceable, or will not be infringed by the product for which the ANDA was submitted.

Patient Support Program: A program that may be offered by a drug’s manufacturer to provide personalized support (including financial support) to patients to improve health outcomes.

PBM: Pharmacy Benefit Manager. Manages pharmacy benefit plans on behalf of insurers and third-party payors, including, e.g., negotiation of network pharmacy discounts, drug manufacturer rebate contracts, and formulary management.

Pharmacodynamics: The study of the biochemical and physiological effects of drugs and the mechanisms of their actions, including the correlation of their actions and effects with their chemical structures.
Pharmacokinetics: The study of the movement of drugs in the body, including the processes of absorption, distribution, and localization in tissues.

Pharmacy Network: A contracted network of pharmacies that receive business from patients covered by a pharmacy benefit plan in exchange for discounts provided to the PBM or third-party payor.

Prior Authorization: A formulary restriction that requires a patient or the patient’s physician to obtain approval from the pharmacy benefit manager before reimbursement for the product will be provided.

Purple Book: A compendium identifying biological products, including any biosimilar and interchangeable biological products, licensed by the FDA under the Public Health Service Act. Comparable to the Orange Book.

Rebate: A post-sale payment or discount that may take various forms in the supply chain for a drug.

REMS: Risk Evaluation and Mitigation Strategy. A post-approval monitoring program required by the FDA for certain drugs.

Sampling: Practice by which pharmaceutical companies and affiliates provide health care practitioners with free samples of pharmaceutical products to provide to their patients.

Small Molecules (SMOLs): Small, chemically manufactured molecules.

SMD: Small Molecule Drugs.

Source Program: Generic drug purchasing programs provided by wholesalers to small chain and independent pharmacies as an alternative to having to order from (or contract with) manufacturers directly.

Specialty Drug: There is no standard classification that defines a set of specialty drugs. Industry participants (e.g., PBMs and CMS) generally define them based on cost per patient and/or handling requirements. They are often not stocked in a typical retail pharmacy.

Step Therapy: A formulary restriction that requires a patient to try and fail on one or more preferred products before a given product will be covered by the pharmacy benefit plan. Also known as a fail-first or step edit restriction.

Therapeutic Equivalence (TE): Drugs classified by the FDA to be therapeutically equivalent can be substituted for one another. For example, generic drugs are typically given “AB” TE codes, which indicate substitutability with a reference product has been demonstrated through evidence supplied via the ANDA.

Tier: Drugs listed on a formulary are typically separated into groups or tiers. Lower formulary tiers are typically associated with lower out-of-pocket costs for the patient (see Formulary).
TPP: Third-party payor. An entity, other than the patient, that pays health care expenses.

TRx: Total Prescriptions.

U&C Price: Usual and Customary Price. In the context of pharmacy reimbursement, this is generally a price submitted by the pharmacy to be used in the absence of a contracted price.

WAC: Wholesaler Acquisition Cost. The list price of a pharmaceutical product.

WAMP: Weighted AMP. Statutorily defined average of submitted AMPs computed by CMS for the computation of FUL.

Wholesaler: A wholesaler generally serves as an intermediary between drug manufacturers and hospitals, clinics, and pharmacies that purchase drugs. For example, it may provide logistical services (e.g., shipping and warehousing) and other services such as supplying data on purchasing to manufacturers, and managing generic source programs.
About NERA

NERA Economic Consulting (www.nera.com) is a global firm of experts dedicated to applying economic, finance, and quantitative principles to complex business and legal challenges. For over half a century, NERA’s economists have been creating strategies, studies, reports, expert testimony, and policy recommendations for government authorities and the world’s leading law firms and corporations. We bring academic rigor, objectivity, and real world industry experience to bear on issues arising from competition, regulation, public policy, strategy, finance, and litigation.

NERA’s clients value our ability to apply and communicate state-of-the-art approaches clearly and convincingly, our commitment to deliver unbiased findings, and our reputation for quality and independence. Our clients rely on the integrity and skills of our unparalleled team of economists and other experts backed by the resources and reliability of one of the world’s largest economic consultancies. With its main office in New York City, NERA serves clients from more than 25 offices across North America, Europe, and Asia Pacific.

Contact
For further information and questions, please contact:

Dr. David Blackburn  
Director  
Washington, DC  
+1 202 466 9264  
david.blackburn@nera.com

Dr. Chris Stomberg  
Associate Director  
Washington, DC  
+1 202 466 9219  
chris.stomberg@nera.com

Dr. Omar Robles  
Senior Consultant  
White Plains, NY  
+1 914 448 4057  
omar.robles@nera.com

The opinions expressed herein do not necessarily represent the views of NERA Economic Consulting or any other NERA consultant. Please do not cite without explicit permission from the authors.